Copyright
©2006 Baishideng Publishing Group Co.
World J Gastroenterol. Sep 28, 2006; 12(36): 5875-5877
Published online Sep 28, 2006. doi: 10.3748/wjg.v12.i36.5875
Published online Sep 28, 2006. doi: 10.3748/wjg.v12.i36.5875
Variables | Value(mean ± SE) | Regressioncoefficient | Standarderror | P |
Age (yr) | 51 ± 1.6 | -0.03 | 0.8 | 0.96 |
Body weight (kg) | 76.5 ± 1.9 | 0.2 | 0.7 | 0.76 |
ALT (U/L) | 59 ± 5.9 | 0.3 | 0.34 | 0.35 |
AST (U/L) | 31 ± 2.9 | -0.3 | 0.84 | 0.67 |
γ-GT (U/L) | 41 ± 6.1 | -0.01 | 0.2 | 0.95 |
Bilirubin (mg/dL) | 0.7 ± 0.04 | 77 | 105.7 | 0.47 |
γ-globulins (mg/dL) | 1.5 ± 0.07 | 2.4 | 17.7 | 0.89 |
Prothrombin time (%) | 95 ± 1.5 | 0.7 | 1.0 | 0.51 |
Albumin (g/L) | 4.8 ± 0.04 | -9.1 | 33.2 | 0.78 |
Cholinesterase (kU/L) | 6.1 ± 0.23 | -1.4 | 6.1 | 0.81 |
Baseline HCV RNA (copies/mL) | 4 705 302 ± 984 817 | 0.02 × 10-5 | 0.2 × 10-5 | 0.31 |
log decline of HCV RNA (baseline wk 12) | 2.7 ± 0.12 | -5.9 | 16.0 | 0.71 |
- Citation: Bojunga J, Sarrazin C, Hess G, Zeuzem S. Elevated plasma levels of N-terminal pro-brain natriuretic peptide in patients with chronic hepatitis C during interferon-based antiviral therapy. World J Gastroenterol 2006; 12(36): 5875-5877
- URL: https://www.wjgnet.com/1007-9327/full/v12/i36/5875.htm
- DOI: https://dx.doi.org/10.3748/wjg.v12.i36.5875